Twice-Daily Bictegravir-Based Therapy Proves Effective and Safe During Rifampicin-Based Tuberculosis Treatment: Insights from the INSIGHT Trial
Highlights
The INSIGHT study confirms that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) achieves 94 percent viral suppression at week 24 in patients with HIV receiving rifampicin-based tuberculosis treatment. No treatment failures or emergent resistance were observed in the bictegravir group, highlighting its robust genetic barrier even in the presence of potent enzyme inducers. Furthermore, the safety profile was manageable, with grade 3 or higher adverse events comparable between the bictegravir and dolutegravir-based control arms, suggesting that BID dosing is a viable clinical strategy for this complex patient population.
Background: The Challenge of HIV-Tuberculosis Co-management
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.